BioSig Technologies, Inc. (NASDAQ:BSGM) Short Interest Down 51.5% in May

BioSig Technologies, Inc. (NASDAQ:BSGM) saw a large decrease in short interest in the month of May. As of May 31st, there was short interest totalling 223,800 shares, a decrease of 51.5% from the May 15th total of 461,700 shares. Based on an average daily trading volume, of 985,800 shares, the short-interest ratio is presently 0.2 days. Currently, 2.0% of the company’s shares are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BioSig Technologies stock. Armistice Capital LLC purchased a new position in BioSig Technologies, Inc. (NASDAQ:BSGM) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,600,000 shares of the company’s stock, valued at approximately $2,660,000. Armistice Capital LLC owned about 62.36% of BioSig Technologies at the end of the most recent quarter. 7.16% of the stock is currently owned by institutional investors.

BioSig Technologies Stock Up 13.9 %

NASDAQ BSGM traded up $0.05 on Friday, hitting $0.45. 191,948 shares of the stock were exchanged, compared to its average volume of 449,832. BioSig Technologies has a 52-week low of $0.20 and a 52-week high of $15.50. The stock has a fifty day moving average price of $1.54 and a two-hundred day moving average price of $1.84.

BioSig Technologies (NASDAQ:BSGM) last released its quarterly earnings results on Monday, May 20th. The company reported ($0.36) EPS for the quarter. The company had revenue of $0.01 million for the quarter.

BioSig Technologies Company Profile

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.